Cargando…
Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1
Apoptosis is a crucial process by which multicellular organisms control tissue growth, removal and inflammation. Disruption of the normal apoptotic function is often observed in cancer, where cell death is avoided by the overexpression of anti-apoptotic proteins of the Bcl-2 (B-cell lymphoma 2) fami...
Autores principales: | Luptak, Jakub, Bista, Michal, Fisher, David, Flavell, Liz, Gao, Ning, Wickson, Kate, Kazmirski, Steven L., Howard, Tina, Rawlins, Philip B., Hargreaves, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union of Crystallography
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834078/ https://www.ncbi.nlm.nih.gov/pubmed/31692474 http://dx.doi.org/10.1107/S2059798319014116 |
Ejemplares similares
-
Design of rigid protein–protein interaction inhibitors enables targeting of undruggable Mcl-1
por: Hargreaves, David, et al.
Publicado: (2023) -
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
por: Tron, Adriana E., et al.
Publicado: (2018) -
Fragment-Sized
Thiazoles in Fragment-Based Drug Discovery
Campaigns: Friend or Foe?
por: Proj, Matic, et al.
Publicado: (2022) -
SHAPE-enabled fragment-based ligand discovery for RNA
por: Zeller, Meredith J., et al.
Publicado: (2022) -
Oxetanes in
Drug Discovery Campaigns
por: Rojas, Juan J., et al.
Publicado: (2023)